Symbols / COEP
COEP Chart
About
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical company. The company is developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its product portfolio and rights are licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform; and DVX201, a clinical-stage, natural killer cell therapy technology. Its product pipeline consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy; and SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological and solid tumors. In addition, the company offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 69.49M |
| Enterprise Value | 59.90M | Income | -12.39M | Sales | 501.00K |
| Book/sh | 2.01 | Cash/sh | 1.00 | Dividend Yield | — |
| Payout | 0.00% | Employees | 5 | IPO | — |
| P/E | — | Forward P/E | -70.94 | PEG | — |
| P/S | 138.71 | P/B | 6.00 | P/C | — |
| EV/EBITDA | -4.96 | EV/Sales | 119.57 | Quick Ratio | 2.00 |
| Current Ratio | 2.21 | Debt/Eq | 2.56 | LT Debt/Eq | — |
| EPS (ttm) | -3.59 | EPS next Y | -0.17 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2024-11-13 16:00 | ROA | -71.41% |
| ROE | -171.91% | ROIC | — | Gross Margin | 72.96% |
| Oper. Margin | -10.43% | Profit Margin | 0.00% | Shs Outstand | 5.76M |
| Shs Float | 4.43M | Short Float | 8.70% | Short Ratio | 8.49 |
| Short Interest | — | 52W High | 21.41 | 52W Low | 6.26 |
| Beta | -0.50 | Avg Volume | 76.94K | Volume | 41.97K |
| Target Price | — | Recom | None | Prev Close | $11.57 |
| Price | $12.06 | Change | 4.24% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$12.06
Latest analyst target
3. DCF / Fair value
$-4.23
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$12.06
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2023-09-22 | init | Ladenburg Thalmann | — → Buy | $3 |
| 2023-05-18 | reit | EF Hutton | Buy → Buy | $6 |
| 2023-05-10 | reit | EF Hutton | — → Buy | $6 |
| 2023-04-19 | init | JonesTrading | — → Buy | $4 |
| 2023-04-05 | reit | EF Hutton | — → Buy | $6 |
| 2023-03-29 | reit | EF Hutton | — → Buy | $6 |
| 2022-12-13 | init | EF Hutton | — → Buy | $6 |
| 2022-12-12 | init | EF Hutton | — → Buy | $6 |
- Coeptis investors clear key hurdle for Z Squared merger - Stock Titan hu, 05 Feb 2026 08
- (COEP) and the Role of Price-Sensitive Allocations - Stock Traders Daily Fri, 20 Feb 2026 04
- SEC clears Coeptis merger proxy as shareholders prepare to vote - Stock Titan ue, 06 Jan 2026 08
- Coeptis Therapeutics Implements Innovative Dual-Track Model to Drive Revenue and Research Efficiency - Quiver Quantitative ue, 23 Sep 2025 07
- Coeptis Therapeutics Holdings (NASDAQ:COEP) Has Debt But No Earnings; Should You Worry? - simplywall.st Wed, 18 Jun 2025 07
- Vanderbilt Report: Coeptis Therapeutics Shareholders Approve Transformational Merger: From Biopharma to Dual-Sector Platform - The Globe and Mail ue, 03 Feb 2026 08
- Coeptis Reprices Equity Awards and Accelerates Option Vesting - TipRanks hu, 12 Feb 2026 08
- Responsive Playbooks and the COEP Inflection - Stock Traders Daily Mon, 09 Feb 2026 08
- Is COEP likely to announce a buyback - 2025 Investor Takeaways & Technical Pattern Alert System - mfd.ru Sat, 21 Feb 2026 02
- DOGE Mining Firm Z Squared Will Go Public Through Merger - CoinDesk Fri, 25 Apr 2025 07
- $44.39B Cell Therapy Market by 2034: Coeptis Pioneers Hybrid Revenue Model While Advancing Cancer Research - Stock Titan ue, 23 Sep 2025 07
- Coeptis Therapeutics Holdings, Inc. Enters Definitive Merger Agreement with Z Squared Inc. to Pursue Dogecoin Mining Venture - Nasdaq Fri, 25 Apr 2025 07
- Coeptis dives 40% on Dogecoin mining pivot with Z Squared merger - The Block Fri, 25 Apr 2025 07
- Coeptis Therapeutics Holdings, Inc. Announces SEC Approval of Merger Registration Statement with Z Squared Inc. - Quiver Quantitative ue, 06 Jan 2026 08
- Coeptis Shareholders Approve Merger, Spin-Out and Rebranding - TipRanks Wed, 04 Feb 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 3250 | — | — | Stock Award(Grant) at price 0.00 per share. | SALKIND GENE | Director | — | 2026-02-11 00:00:00 | D |
| 1 | 5700 | 60192 | — | Conversion of Exercise of derivative security at price 10.56 per share. | SALKIND GENE | Director | — | 2026-02-11 00:00:00 | D |
| 2 | 3250 | — | — | Stock Award(Grant) at price 0.00 per share. | DESCHAMPS PHILIPPE | Director | — | 2026-02-11 00:00:00 | D |
| 3 | 5700 | 60192 | — | Conversion of Exercise of derivative security at price 10.56 per share. | DESCHAMPS PHILIPPE | Director | — | 2026-02-11 00:00:00 | D |
| 4 | 3250 | — | — | Stock Award(Grant) at price 0.00 per share. | CALISE CHRIS | Director | — | 2026-02-11 00:00:00 | D |
| 5 | 5700 | 60192 | — | Conversion of Exercise of derivative security at price 10.56 per share. | CALISE CHRIS | Director | — | 2026-02-11 00:00:00 | D |
| 6 | 12500 | — | — | Stock Award(Grant) at price 0.00 per share. | SHEEHY CHRISTINE ELISE | Officer | — | 2026-02-11 00:00:00 | D |
| 7 | 1000 | 10560 | — | Conversion of Exercise of derivative security at price 10.56 per share. | SHEEHY CHRISTINE ELISE | Officer | — | 2026-02-11 00:00:00 | D |
| 8 | 20000 | — | — | Stock Award(Grant) at price 0.00 per share. | YERACE DANIEL ALEXANDER | Officer and Director | — | 2026-02-11 00:00:00 | D |
| 9 | 10000 | 104100 | — | Conversion of Exercise of derivative security at price 10.41 per share. | YERACE DANIEL ALEXANDER | Officer and Director | — | 2026-02-11 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -8.86M | -20.69M | -32.96M | -12.81M |
| TotalUnusualItems | -578.92K | 567.75K | -3.39M | -2.00K |
| TotalUnusualItemsExcludingGoodwill | -578.92K | 567.75K | -3.39M | -2.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -9.81M | -21.27M | -37.57M | -13.45M |
| ReconciledDepreciation | 1.04M | 1.04M | 1.00M | 447.41K |
| ReconciledCostOfRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -9.44M | -20.12M | -36.35M | -12.81M |
| EBIT | -10.48M | -21.16M | -37.36M | -13.26M |
| NetInterestIncome | -396.12K | -107.69K | -218.41K | -187.13K |
| InterestExpense | 396.12K | 107.69K | 218.41K | 187.13K |
| NormalizedIncome | -9.23M | -21.83M | -34.18M | -13.45M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -9.81M | -21.27M | -37.57M | -13.45M |
| TotalExpenses | 10.05M | 21.49M | 34.20M | 14.12M |
| TotalOperatingIncomeAsReported | -10.05M | -21.49M | -34.20M | -14.05M |
| DilutedAverageShares | 1.92M | 1.28M | 714.78K | 1.02M |
| BasicAverageShares | 1.92M | 1.28M | 714.78K | 1.02M |
| DilutedEPS | -5.10 | -16.56 | -52.60 | -13.16 |
| BasicEPS | -5.10 | -16.56 | -52.60 | -13.16 |
| DilutedNIAvailtoComStockholders | -9.81M | -21.27M | -37.57M | -13.45M |
| NetIncomeCommonStockholders | -9.81M | -21.27M | -37.57M | -13.45M |
| NetIncome | -9.81M | -21.27M | -37.57M | -13.45M |
| MinorityInterests | 1.06M | 0.00 | ||
| NetIncomeIncludingNoncontrollingInterests | -10.88M | -21.27M | -37.57M | -13.45M |
| NetIncomeContinuousOperations | -10.88M | -21.27M | -37.57M | -13.45M |
| TaxProvision | 0.00 | 0.00 | 0.00 | 0.00 |
| PretaxIncome | -10.88M | -21.27M | -37.57M | -13.45M |
| OtherIncomeExpense | -426.81K | 332.27K | -3.16M | 783.79K |
| OtherNonOperatingIncomeExpenses | 152.11K | -235.48K | 233.70K | 785.79K |
| SpecialIncomeCharges | -237.26K | 0.00 | -3.39M | -2.00K |
| OtherSpecialCharges | 200.00K | 3.39M | ||
| WriteOff | 37.26K | 0.00 | 0.00 | 2.00K |
| GainOnSaleOfSecurity | -341.66K | 567.75K | ||
| NetNonOperatingInterestIncomeExpense | -396.12K | -107.69K | -218.41K | -187.13K |
| InterestExpenseNonOperating | 396.12K | 107.69K | 218.41K | 187.13K |
| OperatingIncome | -10.05M | -21.49M | -34.20M | -14.05M |
| OperatingExpense | 10.05M | 21.49M | 34.20M | 14.12M |
| DepreciationAmortizationDepletionIncomeStatement | 1.00M | 1.00M | ||
| DepreciationAndAmortizationInIncomeStatement | 1.00M | 1.00M | ||
| Amortization | 1.00M | 1.00M | ||
| AmortizationOfIntangiblesIncomeStatement | 1.00M | 1.00M | ||
| ResearchAndDevelopment | 2.33M | 6.67M | 20.89K | 0.00 |
| SellingGeneralAndAdministration | 6.72M | 13.82M | 34.18M | 14.12M |
| SellingAndMarketingExpense | 12.71K | 8.33K | 2.92K | |
| GeneralAndAdministrativeExpense | 6.72M | 13.82M | 34.17M | 14.12M |
| OtherGandA | 3.90M | 11.89M | 34.17M | 14.12M |
| SalariesAndWages | 2.83M | 1.93M | ||
| GrossProfit | 0.00 | 0.00 | 0.00 | 75.00K |
| CostOfRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 75.00K |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 75.00K |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 2.12M | 1.77M | 978.34K | 975.84K |
| ShareIssued | 2.12M | 1.77M | 978.34K | 975.84K |
| NetDebt | 804.99K | 1.89M | ||
| TotalDebt | 1.40M | 1.22M | 2.06M | 4.08M |
| TangibleBookValue | 2.64M | 813.96K | 4.45M | 2.35M |
| InvestedCapital | 4.52M | 1.94M | 6.45M | 6.42M |
| WorkingCapital | -3.46M | -1.24M | 1.77M | -585.38K |
| NetTangibleAssets | 2.64M | 813.96K | 4.45M | 2.35M |
| CapitalLeaseObligations | 61.18K | 99.23K | 56.34K | 14.72K |
| CommonStockEquity | 3.19M | 813.96K | 4.45M | 2.35M |
| PreferredStockEquity | 2.00 | 1.00 | ||
| TotalCapitalization | 3.34M | 963.96K | 4.60M | 4.00M |
| TotalEquityGrossMinorityInterest | 3.87M | 813.96K | 4.45M | 2.35M |
| MinorityInterest | 682.06K | 0.00 | ||
| StockholdersEquity | 3.19M | 813.96K | 4.45M | 2.35M |
| OtherEquityInterest | -1.56M | -3.50M | ||
| TreasuryStock | 0.00 | 0.00 | 247.16K | |
| RetainedEarnings | -98.23M | -87.36M | -66.09M | -27.55M |
| AdditionalPaidInCapital | 102.98M | 91.67M | 70.54M | 30.15M |
| CapitalStock | 214.00 | 179.00 | 1.96K | 1.20K |
| CommonStock | 212.00 | 179.00 | 1.96K | 1.20K |
| PreferredStock | 2.00 | 0.00 | 0.00 | 1.00 |
| TotalLiabilitiesNetMinorityInterest | 5.04M | 3.76M | 3.46M | 4.41M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 528.12K | 768.43K | 1.29M | 1.65M |
| DerivativeProductLiabilities | 359.25K | 557.25K | 1.12M | 0.00 |
| LongTermDebtAndCapitalLeaseObligation | 168.88K | 211.18K | 164.72K | 1.65M |
| LongTermCapitalLeaseObligation | 18.88K | 61.18K | 14.72K | 0.00 |
| LongTermDebt | 150.00K | 150.00K | 150.00K | 1.65M |
| CurrentLiabilities | 4.51M | 2.99M | 2.17M | 2.76M |
| OtherCurrentLiabilities | 1.28M | |||
| CurrentDeferredLiabilities | 0.00 | |||
| CurrentDeferredRevenue | 0.00 | |||
| CurrentDebtAndCapitalLeaseObligation | 1.23M | 1.01M | 1.89M | 2.43M |
| CurrentCapitalLeaseObligation | 42.30K | 38.05K | 41.62K | 14.72K |
| CurrentDebt | 1.19M | 975.00K | 1.85M | 2.42M |
| OtherCurrentBorrowings | 1.19M | 975.00K | 1.85M | 2.42M |
| CurrentNotesPayable | 1.09M | 875.00K | 0.00 | |
| PayablesAndAccruedExpenses | 2.01M | 1.98M | 281.02K | 333.22K |
| CurrentAccruedExpenses | 736.88K | 555.95K | 182.00K | 199.13K |
| Payables | 1.27M | 1.42M | 99.02K | 134.09K |
| AccountsPayable | 1.27M | 1.42M | 99.02K | 134.09K |
| TotalAssets | 8.91M | 4.57M | 7.92M | 6.77M |
| TotalNonCurrentAssets | 7.86M | 2.82M | 3.97M | 4.59M |
| OtherNonCurrentAssets | 1.55M | 2.55M | 3.55M | 4.55M |
| NonCurrentPrepaidAssets | 0.00 | 158.33K | 348.33K | 0.00 |
| InvestmentsAndAdvances | 5.69M | 0.00 | ||
| GoodwillAndOtherIntangibleAssets | 541.88K | 0.00 | ||
| OtherIntangibleAssets | 541.88K | |||
| NetPPE | 70.24K | 108.88K | 71.46K | 31.85K |
| AccumulatedDepreciation | -14.78K | -13.93K | -12.70K | -11.31K |
| GrossPPE | 85.02K | 122.81K | 84.15K | 43.16K |
| OtherProperties | 59.78K | 97.57K | 58.91K | 17.93K |
| MachineryFurnitureEquipment | 25.24K | 25.24K | 25.24K | 25.24K |
| CurrentAssets | 1.05M | 1.75M | 3.94M | 2.18M |
| PrepaidAssets | 518.41K | 241.60K | 142.36K | 0.00 |
| Inventory | 0.00 | |||
| Receivables | 0.00 | 38.98K | 8.07K | 0.00 |
| AccruedInterestReceivable | 0.00 | 38.98K | 0.00 | |
| NotesReceivable | 3.50M | 0.00 | ||
| AccountsReceivable | 0.00 | 8.07K | 0.00 | |
| CashCashEquivalentsAndShortTermInvestments | 532.88K | 1.47M | 3.79M | 2.18M |
| CashAndCashEquivalents | 532.88K | 1.47M | 3.79M | 2.18M |
| CashFinancial | 532.88K | 1.47M | 3.79M | 2.18M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -6.65M | -7.24M | -3.88M | -6.24M |
| RepurchaseOfCapitalStock | 0.00 | -247.16K | ||
| RepaymentOfDebt | -650.97K | -1.23M | -2.42M | -1.70M |
| IssuanceOfDebt | 1.85M | 650.00K | 0.00 | 77.59K |
| IssuanceOfCapitalStock | 4.01M | 5.29M | 3.27M | 10.14M |
| CapitalExpenditure | -1.75M | |||
| InterestPaidSupplementalData | 8.77K | 0.00 | 0.00 | 0.00 |
| IncomeTaxPaidSupplementalData | 0.00 | 0.00 | 0.00 | 0.00 |
| EndCashPosition | 532.88K | 1.47M | 3.79M | 2.18M |
| BeginningCashPosition | 1.47M | 3.79M | 2.18M | 202.97K |
| ChangesInCash | -936.25K | -2.32M | 1.61M | 1.98M |
| FinancingCashFlow | 5.71M | 4.92M | 5.49M | 8.22M |
| CashFlowFromContinuingFinancingActivities | 5.71M | 4.92M | 5.49M | 8.22M |
| NetOtherFinancingCharges | -614.58K | -50.90K | ||
| ProceedsFromStockOptionExercised | 500.00K | 200.00K | 5.25M | 0.00 |
| NetPreferredStockIssuance | 3.91M | 0.00 | ||
| PreferredStockIssuance | 3.91M | 0.00 | ||
| NetCommonStockIssuance | 100.00K | 5.29M | 3.27M | 9.89M |
| CommonStockPayments | 0.00 | -247.16K | ||
| CommonStockIssuance | 100.00K | 5.29M | 3.27M | 10.14M |
| NetIssuancePaymentsOfDebt | 1.20M | -575.00K | -2.42M | -1.62M |
| NetShortTermDebtIssuance | 0.00 | |||
| ShortTermDebtPayments | 0.00 | |||
| ShortTermDebtIssuance | 0.00 | |||
| NetLongTermDebtIssuance | 1.20M | -575.00K | -2.42M | -1.62M |
| LongTermDebtPayments | -650.97K | -1.23M | -2.42M | -1.70M |
| LongTermDebtIssuance | 1.85M | 650.00K | 0.00 | 77.59K |
| InvestingCashFlow | 0.00 | 0.00 | 0.00 | -1.75M |
| CashFlowFromContinuingInvestingActivities | 0.00 | -1.75M | ||
| NetIntangiblesPurchaseAndSale | 0.00 | -1.75M | ||
| PurchaseOfIntangibles | 0.00 | -1.75M | ||
| NetPPEPurchaseAndSale | 0.00 | |||
| PurchaseOfPPE | 0.00 | |||
| OperatingCashFlow | -6.65M | -7.24M | -3.88M | -4.49M |
| CashFlowFromContinuingOperatingActivities | -6.65M | -7.24M | -3.88M | -4.49M |
| ChangeInWorkingCapital | -125.26K | 1.73M | -550.34K | -2.98M |
| ChangeInOtherWorkingCapital | 4.23K | 628.00 | -1.00M | |
| ChangeInOtherCurrentLiabilities | 196.95K | -30.32K | ||
| ChangeInOtherCurrentAssets | 0.00 | 2.00K | ||
| ChangeInPayablesAndAccruedExpense | 31.00K | 1.70M | -52.20K | -2.00M |
| ChangeInAccruedExpense | 180.93K | 376.88K | -17.13K | -424.02K |
| ChangeInPayable | -149.94K | 1.32M | -35.07K | -1.58M |
| ChangeInAccountPayable | -149.94K | 1.32M | -35.07K | -1.58M |
| ChangeInPrepaidAssets | -118.47K | 90.75K | -490.69K | 0.00 |
| ChangeInInventory | 0.00 | |||
| ChangeInReceivables | -234.74K | -30.90K | -8.07K | 21.79K |
| ChangesInAccountReceivables | 0.00 | 8.07K | -8.07K | 21.79K |
| OtherNonCashItems | 1.66M | 8.74M | 4.98M | 4.26M |
| StockBasedCompensation | 1.10M | 477.50K | 0.00 | 1.90M |
| AssetImpairmentCharge | 0.00 | |||
| DepreciationAmortizationDepletion | 1.04M | 1.04M | 1.00M | 447.41K |
| DepreciationAndAmortization | 1.04M | 1.04M | 1.00M | 447.41K |
| Depreciation | 1.04M | 1.04M | ||
| OperatingGainsLosses | 549.81K | 2.05M | 28.26M | 5.34M |
| GainLossOnInvestmentSecurities | 349.81K | 2.05M | 28.26M | 5.50M |
| NetIncomeFromContinuingOperations | -10.88M | -21.27M | -37.57M | -13.45M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for COEP
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|